4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Core Insights - 4D Molecular Therapeutics (4DMT) has published significant preclinical data demonstrating the efficacy of its proprietary Therapeutic Vector Evolution (TVE) platform and the R100 vector, which shows up to ~10-fold improvement in transduction and transgene expression compared to AAV2 in human retinal cells [1][2] - The R100 vector-based genetic medicine 4D-150 has shown promising results in nonhuman primate models for wet age-related macular degeneration (wet AMD), leading to robust expression of dual transgenes and complete suppression of severe choroidal neovascularization lesions [1][2] - Ongoing clinical trials for 4D-150 include Phase 1/2 studies for wet AMD (PRISM) and diabetic macular edema (DME) (SPECTRA), with a Phase 3 program for wet AMD expected to initiate in Q1 2025 [1][2] Company Overview - 4DMT is a clinical-stage genetic medicines company focused on developing innovative therapies for large market diseases, particularly in ophthalmology and pulmonology [8] - The company utilizes directed evolution technology to create customized AAV vectors, with R100 being a key product aimed at transforming treatment outcomes for patients with retinal diseases [3][5] - 4DMT is advancing a diverse pipeline of six clinical-stage and one preclinical product candidates targeting various diseases, including wet AMD and DME [8] Disease Context - Wet AMD has an estimated incidence rate of 200,000 new patients annually in the U.S., with a projected prevalence exceeding 4 million individuals in major markets within five years [6] - Diabetic macular edema (DME) affects approximately one million individuals in the U.S., characterized by macular swelling due to blood vessel leakage [7]